{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:59Z","timestamp":1792839899116,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.mcp.2024.101951","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T05:30:17Z","timestamp":1705728617000},"page":"101951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments"],"prefix":"10.1016","volume":"73","author":[{"given":"Maurizio","family":"Capuozzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Santorsola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cinque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Farace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Patrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Nasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-3855","authenticated-orcid":false,"given":"Alessandro","family":"Ottaiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cells9030688","article-title":"New and emerging systemic therapeutic options for advanced cholangiocarcinoma","volume":"9","author":"Massironi","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.mcp.2024.101951_bib2","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3390\/cancers15082368","article-title":"Update on locoregional therapies for cholangiocellular carcinoma","volume":"15","author":"Morawitz","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.mcp.2024.101951_bib3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","article-title":"Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival","volume":"43","author":"Wu","year":"2019","journal-title":"World J. Surg."},{"issue":"11","key":"10.1016\/j.mcp.2024.101951_bib4","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000444562","article-title":"Molecular pathogenesis and current therapy in intrahepatic cholangiocarcinoma","volume":"34","author":"H\u00f8gdall","year":"2016","journal-title":"Dig. Dis."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jhbp.154","article-title":"Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type","volume":"22","author":"Aishima","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"Suppl 1","key":"10.1016\/j.mcp.2024.101951_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib8","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","article-title":"Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity","volume":"66","author":"Moeini","year":"2017","journal-title":"J. Hepatol."},{"issue":"14","key":"10.1016\/j.mcp.2024.101951_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.mcp.2024.101951_bib10","first-page":"1","article-title":"For the TOPAZ-1 investigators. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11523-023-01007-y","article-title":"Durvalumab: a review in advanced biliary tract cancer","volume":"18","author":"Fung","year":"2023","journal-title":"Targeted Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib13","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA A Cancer J. Clin."},{"issue":"15","key":"10.1016\/j.mcp.2024.101951_bib14","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.3390\/cancers13153657","article-title":"Current surgical management of peri-hilar and intra-hepatic cholangiocarcinoma","volume":"13","author":"Lauterio","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/jcm10010104","article-title":"Surgical treatment of intrahepatic cholangiocarcinoma: current and emerging principles","volume":"10","author":"Beal","year":"2020","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.mcp.2024.101951_bib16","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.3390\/cancers15174217","article-title":"Locoregional treatment in intrahepatic cholangiocarcinoma: which treatment for which patient?","volume":"15","author":"Bourien","year":"2023","journal-title":"Cancers"},{"issue":"6586","key":"10.1016\/j.mcp.2024.101951_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay9040","article-title":"Early detection of cancer","volume":"375","author":"Crosby","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.mcp.2024.101951_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315124","article-title":"Evolution of treatment in advanced cholangiocarcinoma: old and new towards precision oncology","volume":"23","author":"Capuozzo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.suronc.2016.12.009","article-title":"Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis","volume":"26","author":"Rahnemai-Azar","year":"2017","journal-title":"Surg Oncol"},{"issue":"4 Pt B","key":"10.1016\/j.mcp.2024.101951_bib21","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.bbadis.2017.08.002","article-title":"The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma","volume":"1864","author":"Macias","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cld.345","article-title":"Biomarkers in cholangiocarcinoma","volume":"3","author":"Marrero","year":"2014","journal-title":"Clin. Liver Dis."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10620-014-3472-0","article-title":"Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma","volume":"60","author":"Huang","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.mcp.2024.101951_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/828074","article-title":"Cholangiocarcinoma: biology, clinical management, and pharmacological perspectives","author":"Macias","year":"2014","journal-title":"ISRN Hepatol"},{"issue":"24","key":"10.1016\/j.mcp.2024.101951_bib25","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.3390\/cancers14246265","article-title":"Surgical aspects of intrahepatic cholangiocarcinoma","volume":"14","author":"Kupietzky","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/hbsn.2016.12.10","article-title":"Multimodality imaging of intrahepatic cholangiocarcinoma","volume":"6","author":"F\u00e1brega-Foster","year":"2017","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib27","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s00261-023-03890-5","article-title":"Distinct radiological features of lymphoepithelioma-like intrahepatic cholangiocarcinoma: comparison with classical intrahepatic cholangiocarcinoma","volume":"48","author":"Liu","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","article-title":"Intrahepatic cholangiocarcinoma","volume":"28","author":"El-Diwany","year":"2019","journal-title":"Surg. Oncol. Clin."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jhbp.156","article-title":"Molecular diagnosis of intrahepatic cholangiocarcinoma","volume":"22","author":"Haga","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4253\/wjge.v8.i3.128","article-title":"Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy","volume":"8","author":"Viterbo","year":"2016","journal-title":"World J. Gastrointest. Endosc."},{"issue":"11","key":"10.1016\/j.mcp.2024.101951_bib31","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1177\/000313481007601119","article-title":"Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma","volume":"76","author":"Tao","year":"2010","journal-title":"Am. Surg."},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib32","first-page":"577","article-title":"Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy","volume":"6","author":"Xie","year":"2016","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12935-022-02550-w","article-title":"KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma","volume":"22","author":"Gao","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"14","key":"10.1016\/j.mcp.2024.101951_bib34","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.3390\/cancers15143579","article-title":"KRAS p.G12C mutation in metastatic colorectal cancer: prognostic implications and advancements in targeted therapies","volume":"15","author":"Ottaiano","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.mcp.2024.101951_bib35","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.mcp.2024.101951_bib36","first-page":"6663","article-title":"Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study","volume":"34","author":"Lumachi","year":"2014","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib37","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/cancers14041026","article-title":"Prognostic and predictive molecular markers in cholangiocarcinoma","volume":"14","author":"Pavicevic","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2024.101951_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2020.00189","article-title":"Mutation of isocitrate dehydrogenase 1 in cholangiocarcinoma impairs tumor progression by inhibiting isocitrate metabolism","volume":"11","author":"Su","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"16","key":"10.1016\/j.mcp.2024.101951_bib39","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2217\/fon-2020-1274","article-title":"Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma","volume":"17","author":"Aguado-Fraile","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.mcp.2024.101951_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 inhibition in cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.mcp.2024.101951_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/105358","article-title":"Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach","volume":"2015","author":"Janvilisri","year":"2015","journal-title":"Dis. Markers"},{"issue":"10","key":"10.1016\/j.mcp.2024.101951_bib42","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1258\/ebm.2012.012215","article-title":"Serum \u03b11\u03b2-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma","volume":"237","author":"Tolek","year":"2012","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021693","article-title":"Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma","volume":"9","author":"Tang","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.mcp.2024.101951_bib44","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cancers14092120","article-title":"Potential role of inflammation-promoting biliary microbiome in primary sclerosing cholangitis and cholangiocarcinoma","volume":"14","author":"Miyabe","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.mcp.2024.101951_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047476","article-title":"Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2024.101951_bib46","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3390\/cells12222590","article-title":"Circulating tumor cells as predictive and prognostic biomarkers in solid tumors","volume":"12","author":"Capuozzo","year":"2023","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067222","article-title":"Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"13","author":"Jiang","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.mcp.2024.101951_bib48","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1245\/s10434-020-08350-8","article-title":"The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma","volume":"27","author":"Moro","year":"2020","journal-title":"Ann. Surg Oncol."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0038-1655775","article-title":"Emerging technologies for the diagnosis of perihilar cholangiocarcinoma","volume":"38","author":"Rizvi","year":"2018","journal-title":"Semin. Liver Dis."},{"issue":"13","key":"10.1016\/j.mcp.2024.101951_bib50","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1245\/s10434-020-08696-z","article-title":"A novel classification of intrahepatic cholangiocarcinoma phenotypes using machine learning techniques: an international multi-institutional analysis","volume":"27","author":"Tsilimigras","year":"2020","journal-title":"Ann. Surg Oncol."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib51","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10620-014-3472-0","article-title":"Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma","volume":"60","author":"Huang","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"7","key":"10.1016\/j.mcp.2024.101951_bib52","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.dld.2015.03.017","article-title":"Relationship between 18-F-fluoro-deoxy-D-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma","volume":"47","author":"Suzuki","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.mcp.2024.101951_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fmed.2020.00113","article-title":"Role of glucose metabolism reprogramming in the pathogenesis of cholangiocarcinoma","volume":"7","author":"Pant","year":"2020","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib54","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.4269\/ajtmh.17-0879","article-title":"Biomarkers for the diagnosis of cholangiocarcinoma: a systematic review","volume":"98","author":"Tshering","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.mcp.2024.101951_bib55","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8489093","article-title":"Connective tissue growth factor in digestive system cancers: a review and meta-analysis","author":"Zhao","year":"2020","journal-title":"BioMed Res. Int."},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1620\/tjem.252.297","article-title":"Diagnostic value of the hypomethylation of the WISP1 promoter in patients with hepatocellular carcinoma associated with hepatitis B virus","volume":"252","author":"Chen","year":"2020","journal-title":"Tohoku J. Exp. Med."},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib57","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11605-011-1813-2","article-title":"Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma","volume":"16","author":"Hirashita","year":"2012","journal-title":"J. Gastrointest. Surg."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib58","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/ijms20061288","article-title":"Mucins: the old, the new and the promising factors in hepatobiliary carcinogenesis","volume":"20","author":"Kasprzak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.mcp.2024.101951_bib59","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/sj.bjc.6604364","article-title":"MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer","volume":"98","author":"Matull","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/mco.2022.2594","article-title":"Expression of MUC1 in different tumours and its clinical significance","volume":"17","author":"Lan","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"9","key":"10.1016\/j.mcp.2024.101951_bib61","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.7150\/ijbs.79126","article-title":"Mucin 4 confers gemcitabine resistance and an unfavorable prognosis in patients with cholangiocarcinoma via AKT activation","volume":"19","author":"Pan","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib62","first-page":"649","article-title":"Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact","volume":"22","author":"Park","year":"2009","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib63","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3892\/ol.2021.13021","article-title":"Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma","volume":"22","author":"Boottanun","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mcp.2024.101951_bib64","article-title":"Dual-specificity phosphatase 11 is a prognostic biomarker of intrahepatic cholangiocarcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib65","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/s41598-022-05914-4","article-title":"Prognostic value of Dickkopf-1 and \u00df-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.mcp.2024.101951_bib66","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3390\/life13102066","article-title":"Targeted therapies in advanced cholangiocarcinoma","volume":"13","author":"Storandt","year":"2023","journal-title":"Life"},{"issue":"10","key":"10.1016\/j.mcp.2024.101951_bib67","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.7150\/thno.56539","article-title":"Mutational spectrum and precision oncology for biliary tract carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib68","article-title":"Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis","volume":"18","author":"Peng","year":"2023","journal-title":"Open Life Sci."},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib69","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.soc.2022.07.007","article-title":"Past, present, and future management of localized biliary tract malignancies","volume":"32","author":"Li","year":"2023","journal-title":"Surg. Oncol. Clin."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib71","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/jjco\/hyab029","article-title":"Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma","volume":"51","author":"Tsujie","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Rizvi","year":"2017","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib73","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib75","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.mcp.2024.101951_bib76","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib77","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib78","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.mcp.2024.101951_bib79","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol."},{"issue":"7","key":"10.1016\/j.mcp.2024.101951_bib80","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14656566.2023.2202814","article-title":"The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma","volume":"24","author":"Ruff","year":"2023","journal-title":"Expet Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4251\/wjgo.v13.i5.332","article-title":"Liquid biopsy in cholangiocarcinoma: current status and future perspectives","volume":"13","author":"Rompianesi","year":"2021","journal-title":"World J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.mcp.2024.101951_bib83","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41571-022-00660-y","article-title":"Circulating tumour DNA - looking beyond the blood","volume":"19","author":"Tivey","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.mcp.2024.101951_bib84","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.3390\/ijms23105343","article-title":"Basic science with preclinical models to investigate and develop liquid biopsy: what are the available data and is it a fruitful approach?","volume":"23","author":"Cena","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2024.101951_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940473","article-title":"Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?","volume":"12","author":"Gonvers","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2024.101951_bib86","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1245\/s10434-023-13126-x","article-title":"Optimizing circulating tumour DNA use in the perioperative setting for intrahepatic cholangiocarcinoma: diagnosis, screening, minimal residual disease detection and treatment response monitoring","volume":"30","author":"Choi","year":"2023","journal-title":"Ann. Surg Oncol."},{"issue":"11","key":"10.1016\/j.mcp.2024.101951_bib87","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.mcp.2024.101951_bib88","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.mcp.2024.101951_bib89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/onco.13844","article-title":"Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns","volume":"26","author":"Israel","year":"2021","journal-title":"Oncol."},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/cancers14010233","article-title":"Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing","volume":"14","author":"Csoma","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib91","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.27944","article-title":"Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma","volume":"63","author":"Yang","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.mcp.2024.101951_bib92","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4174\/astr.2021.101.3.140","article-title":"Circulating microRNAs as biomarkers in bile-derived exosomes of cholangiocarcinoma","volume":"101","author":"Han","year":"2021","journal-title":"Ann Surg Treat Res"},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib93","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/life13051117","article-title":"Role of extracellular vesicles in liver diseases","volume":"13","author":"Tamasi","year":"2023","journal-title":"Life"},{"issue":"24","key":"10.1016\/j.mcp.2024.101951_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416217","article-title":"Extracellular vesicles as biomarkers in liver disease","volume":"23","author":"Mu\u00f1oz-Hern\u00e1ndez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib95","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/liv.15490","article-title":"Extracellular vesicles in fatty liver disease and steatohepatitis: role as biomarkers and therapeutic targets","volume":"43","author":"Eguchi","year":"2023","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib96","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/hep.31493","article-title":"A circular RNA, cholangiocarcinoma-associated circular RNA 1, contributes to cholangiocarcinoma progression, induces angiogenesis, and disrupts vascular endothelial barriers","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib97","article-title":"Emerging roles of circular RNAs in liver cancer","volume":"4","author":"Louis","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib98","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13046-023-02699-w","article-title":"CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN\/AKT pathway in intrahepatic cholangiocarcinoma","volume":"42","author":"Liao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib99","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2021.08.027","article-title":"Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription","volume":"76","author":"Chen","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mcp.2024.101951_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215980","article-title":"Circular RNAs in cholangiocarcinoma","volume":"553","author":"Liao","year":"2023","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.mcp.2024.101951_bib101","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/ncb3623","article-title":"A non-coding function of TYRP1 mRNA promotes melanoma growth","volume":"19","author":"Gilot","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib102","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2007.05.017","article-title":"Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures","volume":"47","author":"Lempinen","year":"2007","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.mcp.2024.101951_bib103","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1478-3231.2011.02672.x","article-title":"Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity","volume":"32","author":"Halme","year":"2012","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.mcp.2024.101951_bib104","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13277-012-0597-7","article-title":"Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma","volume":"34","author":"Jamnongkan","year":"2013","journal-title":"Tumour Biol"},{"issue":"4","key":"10.1016\/j.mcp.2024.101951_bib105","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ijc.26443","article-title":"Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma","volume":"131","author":"Prakobwong","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.mcp.2024.101951_bib106","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1007\/s00464-013-3025-1","article-title":"High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study","volume":"27","author":"Jo","year":"2013","journal-title":"Surg. Endosc."},{"issue":"1","key":"10.1016\/j.mcp.2024.101951_bib107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","article-title":"Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma","volume":"79","author":"Lapitz","year":"2023","journal-title":"J. Hepatol."}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850824000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850824000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:18:41Z","timestamp":1760192321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850824000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":107,"alternative-id":["S0890850824000033"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2024.101951","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2024.101951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101951"}}